TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07175493: A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

Sponsor: Keymed Biosciences Co.Ltd · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 158 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07175493 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07175493 Rescue Dossier →